Dr Kassoum Nacro received his Master Degree in Biochemistry, Molecular Biology and Organic Chemistry (1992) and his Doctorate with honors in the field of Organic synthesis (1995) from Paul Sabatier University (Toulouse, France). From 1996 to 1999, he was a postdoctoral fellow at the National Cancer Institute of NIH and was appointed at Georgetown University, Lombardi Cancer Center as a Faculty in 1999. In these two institutions his research foci was discovering anti-cancer agents and his teams and he developed allosteric modulators of PKC, disruptors of protein-protein interaction involving anti-apoptotic agent Bcl2 and tyrosine kinase inhibitors against HER2.
Dr Nacro years at Albany Molecular Research Inc where divided between medicinal chemistry outsourcing services to the pharmaceutical industry at first and then to internal drug discovery projects. He has worked in disease areas encompassing cancer, inflammation and CNS. His contributions at AMRI led to compounds reaching clinical trials for cancer and depression indications.
He joined Experimental Therapeutics Center a research institute of A*STAR in 2009 where he aims at discovering anti-cancer, anti-viral and anti-bacterial drugs. These projects are all conducted in close collaboration with external partners in or out of Singapore with a cutting edge expertise on the molecular targets relevance to diseases with unmet therapeutic needs.